RESEARCH TRIANGLE PARK, NC--(Marketwire - June 23, 2009) - According to Cutting Edge Information's latest therapeutic area report "Autoimmune Market Forecast to 2014" (, autoimmune brand revenues will grow by 76% over the next five years to nearly $70 billion in annual sales.

With 43 brands profiled in the report, this comes to an average $1.6 billion per brand. While massive blockbusters -- such as Humira with its projected $9.8 billion in 2014 sales -- offset some of the smaller drugs, many of the profiled brands exhibit blockbuster potential. For instance, several of the profiled Phase 2 compounds should easily eclipse $1 billion in sales but will not hit this mark before 2014, thanks to anticipated launch dates in 2011 and 2012.

"The autoimmune market presents a tremendous opportunity for large and mid-sized pharmaceutical companies looking to replace products going off patent and for the dozens of small biotechs with autoimmune research looking to salvage their companies," says Shaylyn Pike, lead author of the report. "Pharma needs these high-yield compounds and will pay top dollar to get them, and companies without established autoimmune programs will pay a premium for the technology behind the compounds, as well."

"Autoimmune Market Forecast to 2014" presents breakdowns of 43 individual drugs and 12 classes. Besides providing in-depth market analysis for each product, it compares data across brands, classes and company portfolios -- leading to an honest and accurate evaluation of performance: advantages, potential pitfalls, competitive threats, and clinical successes and failures.

The report is organized into indication snapshots, brand profiles and drug manufacturer profiles:

Indication snapshots provide an overview of each of the six main autoimmune indications and their associated complications. Analysis includes a look at the indication's history, pathology, epidemiology and treatment regimens.

Brand Profiles detail a product's competitive and strategic positioning, market opportunities, and patent and litigation data. Profiles include:

--  Drug's current and projected competitive strength
--  Sales projection charts through 2014
--  Materiality charts
--  Clinical trial information
--  Patent/market exclusivity tables

Company Profiles show breakdowns for the nine companies with the highest-grossing autoimmune portfolios. Profiles contain:

--  Ranking within market
--  Strengths analysis
--  Growth areas analysis
--  Key products breakdown
Download a complimentary report brochure at

Contact Information: CONTACT: Shaylyn Pike 919-433-0385